DEKA: US FDA approves Unity Subcutaneous Delivery System for Remodulin to trear PAH

United Therapeutics Corporation and DEKA Research & Development Corp. announced receipt of 510(k) clearance by the US Food and Drug Administration (FDA) for the Unity Subcutaneous Delivery System for Remodulin (treprostinil) injection